Amneal Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AMRX Nasdaq 2830 amneal.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Amneal Pharmaceuticals, Inc.

Amneal to Participate at Upcoming Investor Conference - Mar 10th, 2025 8:05 pm
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - Mar 3rd, 2025 9:05 pm
Amneal Pharmaceuticals Full Year 2024 Earnings: EPS Misses Expectations - Mar 1st, 2025 2:10 pm
Amneal Reports Fourth Quarter and Full Year 2024 Financial Results - Feb 28th, 2025 11:00 am
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Feb 19th, 2025 1:00 pm
Although Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders have sold lately, they have the highest ownership with 51% stake - Feb 13th, 2025 10:53 am
7MM PD market to grow by $4.5bn between 2023 and 2033 - Jan 30th, 2025 11:22 am
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025 - Jan 29th, 2025 1:30 pm
Kashiv Biosciences’ Phase I trial of KSHB002 injection meets primary endpoints - Jan 29th, 2025 12:25 pm
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin - Jan 23rd, 2025 1:00 pm
Amneal to Participate at Upcoming Investor Conferences - Dec 4th, 2024 1:00 pm
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist - Nov 21st, 2024 9:05 pm
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Nov 9th, 2024 9:01 pm
Amneal Reports Third Quarter 2024 Financial Results - Nov 8th, 2024 11:00 am
Amneal Pharmaceuticals (NASDAQ:AMRX) grows 3.0% this week, taking five-year gains to 211% - Oct 31st, 2024 2:42 pm
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets - Oct 21st, 2024 12:00 pm
Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Oct 9th, 2024 10:10 pm
Amneal to Report Third Quarter 2024 Results on November 8, 2024 - Oct 8th, 2024 8:05 pm
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases - Oct 1st, 2024 10:00 am
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease - Sep 23rd, 2024 12:00 pm